Relapse prevention for addictive behaviors

The Relapse Prevention (RP) model has been a mainstay of addictions theory and treatment since its introduction three decades ago. This paper provides an overview and update of RP for addictive behaviors with a focus on developments over the last decade (2000-2010). Major treatment outcome studies and meta-analyses are summarized, as are selected empirical findings relevant to the tenets of the RP model. Notable advances in RP in the last decade include the introduction of a reformulated cognitive-behavioral model of relapse, the application of advanced statistical methods to model relapse in large randomized trials, and the development of mindfulness-based relapse prevention. We also review the emergent literature on genetic correlates of relapse following pharmacological and behavioral treatments. The continued influence of RP is evidenced by its integration in most cognitive-behavioral substance use interventions. However, the tendency to subsume RP within other treatment modalities has posed a barrier to systematic evaluation of the RP model. Overall, RP remains an influential cognitive-behavioral framework that can inform both theoretical and clinical approaches to understanding and facilitating behavior change

Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead

There is growing interest in non-invasive brain stimulation (NIBS) as a novel treatment option for substance-use disorders (SUDs). Recent momentum stems from a foundation of preclinical neuroscience demonstrating links between neural circuits and drug consuming behavior, as well as recent FDA-approval of NIBS treatments for mental health disorders that share overlapping pathology with SUDs. As with any emerging field, enthusiasm must be tempered by reason; lessons learned from the past should be prudently applied to future therapies. Here, an international ensemble of experts provides an overview of the state of transcranial-electrical (tES) and transcranial-magnetic (TMS) stimulation applied in SUDs. This consensus paper provides a systematic literature review on published data – emphasizing the heterogeneity of methods and outcome measures while suggesting strategies to help bridge knowledge gaps. The goal of this effort is to provide the community with guidelines for best practices in tES/TMS SUD research. We hope this will accelerate the speed at which the community translates basic neuroscience into advanced neuromodulation tools for clinical practice in addiction medicine

Evaluation of Contingency Management (CM) for Substance Use Disorder (SUD)

This document includes a formal evaluation of contingency management for substance use disorder per the Tolin et al., (2015) criteria

Limitations of cross-lagged panel models in addiction research and alternative models: An empirical example using project MATCH.

Objective: Models of addiction often posit bidirectional and dynamic associations between constructs relevant to the etiology and maintenance of addictive behaviors. The cross-lagged panel model (CLPM) is commonly used in addiction research but has been critiqued for not appropriately adjusting for between-person variance. Alternatives to the CLPM have been suggested but remain underutilized. The primary purpose of this article is to highlight interpretational limitations of the CLPM and to provide examples of alternative models. Method: We specified CLPM, Random-Intercept CLPM, and a Latent Curve Model with Structured Residuals using four waves of data from Project MATCH (n = 1,201). We modeled prospective relations among depression symptoms and temptation to drink. Substantive inferences and assumptions across models were compared. Results: The CLPM provided the most evidence of significant cross-lagged paths but the poorest fit to the data compared to other models. Alternative models found little evidence of prospective within-person associations, and more evidence for between-person associations and wave-specific within-person relations between depression symptoms and temptation to drink. Conclusions: This study highlights shortcomings of the CLPM and details alternative models to consider. Addiction researchers should consider alternatives to the CLPM to more optimally delineate relations among constructs across time. A commonly used modeling approach in addiction research, the cross-lagged panel model has significant interpretational limitations. Alternative models that accommodate within- and between-person change are recommended. (PsycInfo Database Record (c) 2021 APA, all rights reserved

Study protocol for the healing opioid misuse and pain through engagement trial: integrated treatment for individuals with co-occurring chronic pain and opioid use disorder

Chronic pain and opioid use disorder (OUD) are public health crises and their co-occurrence has led to further complications and public health impacts. Provision of treatments for comorbid chronic pain and OUD is paramount to address these public health crises. Medications for OUD (MOUD) are gold standard treatments for OUD that have also demonstrated benefit in pain management. However, clinics that provide MOUD for chronic pain or OUD often lack behavioral treatments to address the challenges experienced by individuals with both conditions. Developing and implementing a behavioral treatment that complements MOUD may better equip clinics to provide comprehensive care to the growing proportion of clients who present with comorbid chronic pain and OUD. In the Healing Opioid misuse and Pain through Engagement (HOPE) Trial, we are using an effectiveness-implementation hybrid design to examine the benefits of an integrated behavioral treatment and to determine the feasibility of implementing the integrated treatment into clinics that provide MOUD. The treatment integrated 2 evidence-based treatments-Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention-to target the emotional, behavioral, and physiological sequelae of OUD and chronic pain. Implementation feasibility will include assessing changes in implementation readiness and identifying facilitators and barriers to implementing the integrated treatment among all personnel employed in clinics that provide MOUD. This commentary offers an overview of the study and design and details adaptations we made to our study protocol, based largely on clinic personnel time constraints and variable clinic procedures during the COVID-19 pandemic.</p